1-((3-hydroxy-4-methoxy)-1-naphthoxy)-2,3-propanediol has been researched along with citalopram in 1 studies
| Studies (1-((3-hydroxy-4-methoxy)-1-naphthoxy)-2,3-propanediol) | Trials (1-((3-hydroxy-4-methoxy)-1-naphthoxy)-2,3-propanediol) | Recent Studies (post-2010) (1-((3-hydroxy-4-methoxy)-1-naphthoxy)-2,3-propanediol) | Studies (citalopram) | Trials (citalopram) | Recent Studies (post-2010) (citalopram) |
|---|---|---|---|---|---|
| 9 | 4 | 1 | 5,348 | 1,424 | 2,350 |
| Protein | Taxonomy | 1-((3-hydroxy-4-methoxy)-1-naphthoxy)-2,3-propanediol (IC50) | citalopram (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.297 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.196 | |
| Aromatase | Rattus norvegicus (Norway rat) | 0.0018 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.196 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 3.289 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.297 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0227 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.0027 | |
| Histamine H1 receptor | Homo sapiens (human) | 3.194 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.839 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.1869 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.398 | |
| Transporter | Rattus norvegicus (Norway rat) | 8.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anttila, M; Heinonen, E; Helminen, A; Huupponen, R; Laine, K; Mäki-Ikola, O; Reinikainen, K; Scheinin, M | 1 |
1 trial(s) available for 1-((3-hydroxy-4-methoxy)-1-naphthoxy)-2,3-propanediol and citalopram
| Article | Year |
|---|---|
Lack of adverse interactions between concomitantly administered selegiline and citalopram.
Topics: Adult; Antidepressive Agents; Citalopram; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Epinephrine; Humans; Hydroxyindoleacetic Acid; Male; Monoamine Oxidase Inhibitors; Naphthols; Norepinephrine; Placebos; Prolactin; Propylene Glycols; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin | 1997 |